Ok, so the South African variant is bad news...
The vaccine, developed with Oxford, was found not to prevent the virus variant rampant in South Africa from causing mild or moderate disease. In the U.S., Super Bowl parties raise worries about new surges.
www.nytimes.com
South Africa halted use of the AstraZeneca-Oxford coronavirus vaccine on Sunday after evidence emerged that the vaccine did not protect clinical-trial participants from mild or moderate illness caused by the more contagious virus variant that was first seen there.
Scientists in South Africa said on Sunday that a similar problem held among people who had been infected by earlier versions of the coronavirus: the immunity they acquired naturally did not appear to protect them from mild or moderate cases when reinfected by the variant, known as B.1.351....The B.1.351 variant has already spread to at least 32 countries, including the United States.
It was not clear from the studies outlined by South African scientists on Sunday whether the AstraZeneca-Oxford vaccine protected against severe disease from the B.1.351 variant.
The clinical trial participants who were evaluated were relatively young and unlikely to become severely ill, making it impossible for the scientists to determine if the variant interfered with the AstraZeneca-Oxford vaccine’s ability to protect against severe Covid-19, hospitalizations, or deaths.
However, based on the immune responses detected in blood samples from people who were given the vaccine, the scientists said they believed that the vaccine could yet protect against more severe cases.
If further studies show that it does, South African health officials said on Sunday that they would consider resuming use of the AstraZeneca-Oxford vaccine.
A more contagious variant of the coronavirus first found in Britain is spreading rapidly in the United States, doubling roughly every 10 days, according to a new study.
Analyzing half a million coronavirus tests and hundreds of genomes, a team of researchers predicted that in a month this variant could become predominant in the United States, potentially bringing a surge of new cases and increased risk of death.
The new research offers the first nationwide look at the history of the variant, known as B.1.1.7, since it arrived in the United States in late 2020. Last month, the Centers for Disease Control and Prevention warned that B.1.1.7 could become predominant by March if it behaved the way it did in Britain. The new study confirms that projected path.